These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 22697477)

  • 1. Treatment of ovarian hyperstimulation syndrome using gonadotropin releasing hormone antagonist: a pilot study.
    Hosseini MA; Mahdavi A; Aleyasin A; Safdarian L; Bahmaee F
    Gynecol Endocrinol; 2012 Nov; 28(11):853-5. PubMed ID: 22697477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of GnRH agonists and antagonists in assisted reproduction cycles of patients at high risk of ovarian hyperstimulation syndrome.
    Ragni G; Vegetti W; Riccaboni A; Engl B; Brigante C; Crosignani PG
    Hum Reprod; 2005 Sep; 20(9):2421-5. PubMed ID: 15890731
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing hormone antagonist protocol in combination with a "freeze-all" strategy: a prospective multicentric study.
    Griesinger G; Schultz L; Bauer T; Broessner A; Frambach T; Kissler S
    Fertil Steril; 2011 May; 95(6):2029-33, 2033.e1. PubMed ID: 21371705
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor cycles: findings of a large retrospective cohort study.
    Bodri D; Guillén JJ; Galindo A; Mataró D; Pujol A; Coll O
    Fertil Steril; 2009 Feb; 91(2):365-71. PubMed ID: 18367175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum vascular endothelial growth factor levels following luteal gonadotrophin-releasing hormone antagonist administration in women with severe early ovarian hyperstimulation syndrome.
    Lainas GT; Kolibianakis EM; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas TG; Tarlatzis BC
    BJOG; 2014 Jun; 121(7):848-55. PubMed ID: 24621101
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ovarian hyperstimulation syndrome prevention strategies: use of gonadotropin-releasing hormone antagonists.
    Griesinger G
    Semin Reprod Med; 2010 Nov; 28(6):493-9. PubMed ID: 21082508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series.
    Rollene NL; Amols MH; Hudson SBA; Coddington CC
    Fertil Steril; 2009 Sep; 92(3):1169.e15-1169.e17. PubMed ID: 19608177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Papanikolaou EG; Pozzobon C; Kolibianakis EM; Camus M; Tournaye H; Fatemi HM; Van Steirteghem A; Devroey P
    Fertil Steril; 2006 Jan; 85(1):112-20. PubMed ID: 16412740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Management of severe early ovarian hyperstimulation syndrome by re-initiation of GnRH antagonist.
    Lainas TG; Sfontouris IA; Zorzovilis IZ; Petsas GK; Lainas GT; Kolibianakis EM
    Reprod Biomed Online; 2007 Oct; 15(4):408-12. PubMed ID: 17908403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High doses of GnRH antagonists are efficient in the management of severe ovarian hyperstimulation syndrome.
    Bonilla-Musoles FM; Raga F; Castillo JC; Sanz M; Dolz M; Osborne N
    Clin Exp Obstet Gynecol; 2009; 36(2):78-81. PubMed ID: 19688946
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of gonadotropin-releasing hormone agonists and antagonists in assisted reproduction cycles of polycystic ovarian syndrome patients.
    Hosseini MA; Aleyasin A; Saeedi H; Mahdavi A
    J Obstet Gynaecol Res; 2010 Jun; 36(3):605-10. PubMed ID: 20598044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical application of gonadotropin-releasing hormone antagonist in Chinese women undergoing controlled ovarian hyperstimulation for in vitro fertilization and embryo transfer].
    Chen SL; Yin MN; Sun L; Li H; Chen X; Song HD; He JX; Zhu L; Xing FQ
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 May; 27(5):588-90. PubMed ID: 17545062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Double GnRH-antagonist dose before HCG administration may prevent OHSS in oocyte-donor cycles: a pilot study.
    Prapas Y; Panagiotidis I; Kalogiannidis I; Gjata E; Papatheodorou A; Prapa S; Kasapi L; Goudakou M; Prapas N
    Reprod Biomed Online; 2010 Aug; 21(2):159-65. PubMed ID: 20627811
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Elective cryopreservation of all pronuclear oocytes after GnRH agonist triggering of final oocyte maturation in patients at risk of developing OHSS: a prospective, observational proof-of-concept study.
    Griesinger G; von Otte S; Schroer A; Ludwig AK; Diedrich K; Al-Hasani S; Schultze-Mosgau A
    Hum Reprod; 2007 May; 22(5):1348-52. PubMed ID: 17303632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of low-dose human chorionic gonadotropin (hCG) in a GnRH antagonist protocol.
    Koichi K; Yukiko N; Shima K; Sachiko S
    J Assist Reprod Genet; 2006 May; 23(5):223-8. PubMed ID: 16786420
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of GnRH antagonist fixed protocol and GnRH agonists long protocol in infertile patients with normal ovarian reserve function in their first in vitro fertilization-embryo transfer cycle].
    Yang S; Chen XN; Qiao J; Liu P; Li R; Chen GA; Ma CH
    Zhonghua Fu Chan Ke Za Zhi; 2012 Apr; 47(4):245-9. PubMed ID: 22781108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study.
    Bahçeci M; Ulug U; Ben-Shlomo I; Erden HF; Akman MA
    J Reprod Med; 2005 Feb; 50(2):84-90. PubMed ID: 15755044
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum inhibin A, VEGF and TNFalpha levels after triggering oocyte maturation with GnRH agonist compared with HCG in women with polycystic ovaries undergoing IVF treatment: a prospective randomized trial.
    Babayof R; Margalioth EJ; Huleihel M; Amash A; Zylber-Haran E; Gal M; Brooks B; Mimoni T; Eldar-Geva T
    Hum Reprod; 2006 May; 21(5):1260-5. PubMed ID: 16439507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sequential E2 levels not ovarian maximal diameter estimates were correlated with outcome of cetrotide therapy for management of women at high-risk of ovarian hyperstimulation syndrome: a randomized controlled study.
    Salama KM; Abo Ragab HM; El Sherbiny MF; Morsi AA; Souidan II
    BMC Womens Health; 2017 Nov; 17(1):108. PubMed ID: 29132339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparisons of different dosages of gonadotropin-releasing hormone (GnRH) antagonist, short-acting form and single, half-dose, long-acting form of GnRH agonist during controlled ovarian hyperstimulation and in vitro fertilization.
    Hsieh YY; Chang CC; Tsai HD
    Taiwan J Obstet Gynecol; 2008 Mar; 47(1):66-74. PubMed ID: 18400585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.